Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Pre-Transplant Multiparameter Flow Cytometric Measurable Residual Disease in Acute Myeloid Leukemia As an Independent Prognostic Factor for Survival after Myeloablative Allogeneic Hematopoietic Cell Transplantation

Blood (2022) 140 (Supplement 1): 7747–7749.

https://doi.org/10.1182/blood-2022-167407

Published: 2022

Journal Articles

Prospective Assessment of Measurable Residual Disease Kinetics in Intensively Treated Patients with Acute Myeloid Leukemia - Results of the Polish Adult Leukemia Group PALG-AML1/2016 Study

Blood (2022) 140 (Supplement 1): 6241–6243.

https://doi.org/10.1182/blood-2022-156950

Published: 2022

Journal Articles

A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)

Blood (2022) 140 (Supplement 1): 9013–9015.

https://doi.org/10.1182/blood-2022-166184

Published: 2022

Journal Articles

Association of Inflammatory Cytokines with Clonal Hematopoiesis and Progression to Acute Myeloid Leukemia

Pinkal Desai, Mayumi Sugita, Rachel Heise, Madison Thies, Nuria Mencia Trinchant, Cynthia Crispino, Sharmaine Griffith-Baker, Rejxhis Prifti, Ashwini Kumar, Michael Samuel, Justin D. Kaner, Ellen Ritchie, Wendy Cozen, Michael S. Simon, Gail J. Roboz, Monica L. Guzman

Blood (2022) 140 (Supplement 1): 8602–8604.

https://doi.org/10.1182/blood-2022-166825

Published: 2022

Journal Articles

PTPN11 mutations Confer Adverse Outcomes and Therapy Resistance in Older Patients with Acute Myeloid Leukemia (AML)

Dennis Lee, Tyler Augi, Kata Alilovic, Nuria Mencia Trinchant, Eti Sinha, Jorge Contreras, Michael Samuel, Pinkal Desai, Michael Kluk, Brianna N Smith, Gail J. Roboz, Ellen Ritchie, Michael R. Savona, Monica L. Guzman, Justin D. Kaner

Blood (2022) 140 (Supplement 1): 3208–3209.

https://doi.org/10.1182/blood-2022-167068

Published: 2022

Journal Articles

Safety and Efficacy of Lower Intensity Induction Therapy with Intravenous Prexigebersen (BP1001) in Patients with High-Risk and Relapsed/Refractory Acute Myeloid Leukemia (AML)

Maro Ohanian, Tara L. Lin, Ellen Ritchie, Michael Craig, Apurv Agrawal, Kathleen G. Halka, Naveen Pemmaraju, Gautam Borthakur, Miranda Lim, Sherry A. Pierce, Ana Tari Ashizawa, Hagop Kantarjian, Jorge E. Cortes, Gail J. Roboz

Blood (2021) 138 (Supplement 1): 1281.

https://doi.org/10.1182/blood-2021-152750

Published: 2021

Journal Articles

Impact of Peri-Transplant Molecular Mutations on Outcomes of AML Patients Undergoing Fludarabine/Melphalan Conditioned Allogeneic Stem Cell Transplant

Mateo Mejia Saldarriaga, Yassine Tahri, Sangmin Lee, Zhengming Chen, Tsiporah B. Shore, Danielle Guarneri, Sebastian A. Mayer, Adrienne A. Phillips, Alexandra Gomez-Arteaga, Pinkal Desai, Ellen Ritchie, Michael B. Samuel, Gail J. Roboz, Koen van Besien, Jingmei Hsu

Blood (2021) 138 (Supplement 1): 4833.

https://doi.org/10.1182/blood-2021-149297

Published: 2021

Journal Articles

Comparing Outcomes between Liposomal Daunorubicin/Cytarabine (CPX-351) and HMA+Venetoclax As Frontline Therapy in Acute Myeloid Leukemia

Blood (2021) 138 (Supplement 1): 32.

https://doi.org/10.1182/blood-2021-145947

Published: 2021

Journal Articles

Venetoclax in Combination with Gilteritinib Demonstrates Molecular Clearance of FLT3 mutation in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia

Naval Daver, Alexander E. Perl, Joseph Maly, Mark Levis, Ellen Ritchie, Mark R. Litzow, James McCloskey, Catherine C. Smith, Gary J. Schiller, Terrence Bradley, Ramon V. Tiu, Kiran Naqvi, Monique Dail, Satya Siddani, Jing Wang, Brenda Chyla, Paul Lee, Jessica K. Altman

Blood (2021) 138 (Supplement 1): 691.

https://doi.org/10.1182/blood-2021-150743

Published: 2021

Journal Articles

The Prognostic Value of Early Measurable Residual Disease Assessment in Patients with Acute Myeloid Leukemia Treated with Intensive Chemotherapy - Preliminary Results of Polish Adult Leukemia Group PALG-AML1/2016 Study

Blood (2021) 138 (Supplement 1): 3453.

https://doi.org/10.1182/blood-2021-153520

Published: 2021

Journal Articles

Hematopoietic Stem and Progenitor Cell Fitness As a Novel Prognostic and Monitoring Biomarker for JAK2 V617F Myeloproliferative Neoplasms (MPNs)

Ghaith Abu-Zeinah, Silvana Di Giandomenico, Tatiana Cruz, Daniel Choi, Elwood Taylor, III, Ellen Ritchie, Richard T. Silver, Joseph Scandura

Blood (2021) 138 (Supplement 1): 627.

https://doi.org/10.1182/blood-2021-153003

Published: 2021

Journal Articles

Community Versus Academic Practice in Essential Thrombocythemia and Myelofibrosis: Differences in Clinical Characteristics, Diagnosis, Treatment Patterns, and Symptom Burden (Analysis of Data from the MOST Study)

Roger Lyons, David Lessen, Salman Fazal, Robyn Scherber, Patricia Kalafut, Haobo Ren, Ellen Ritchie

Blood (2021) 138 (Supplement 1): 1497.

https://doi.org/10.1182/blood-2021-145909

Published: 2021

Journal Articles

Pain and Opioid Use in Patients with FLT3 Mutation-Positive Relapsed/Refractory AML: A Subanalysis of Patient-Reported Outcomes from the Admiral Trial

David Cella, PhD, Ellen Ritchie, MD, Arnaud Pigneux, MD PhD, Yoshinobu Kanda, MD PhD, Cristina Ivanescu, PhD, Bhavik J. Pandya, PharmD, Manasee V. Shah, MPH

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-134389

Published: 2020

Journal Articles

A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)

Agnieszka Wierzbowska, MDPhD, Agnieszka Pluta, MDPhD, Marta Antonina Libura, MDPhD, Anna Czyz, MDPhD, Sebastian Giebel, MDPhD, Piotr Stelmach, MDPhD, Magdalena Czemerska, MDPhD, Anna Kopinska, MD, Krzysztof Wozniczka, MDPhD, Grzegorz Helbig, MDPhD, Karol Wojcik, MD, Malgorzata Razny, MDPhD, Marta Sobas, MDPhD, Tomasz Wrobel, MDPhD, Andrzej Szczepaniak, MDPhD, Lidia Gil, MDPhD, Alicja Sadowska-Klasa, MD, Jan Zaucha, MDPhD, Tomasz Gromek, MDPhD, Marek Hus, MDPhD, Edyta Cichocka, MDPhD, Janusz Halka, MDPhD, Elzbieta Patkowska, Jolanta Wozniak, PhD, Agata Obara, MD, Beata Blajer-Olszewska, MD, Katarzyna Dulik, MD, Jerzy Holowiecki, MDPhD, Michal Soin, M.Sc., Tadeusz Robak, MDPhD, Nicole M. Cruz, MD, Nuria Mencia-Trinchant, PhD, Pinkal Desai, MDMPH, Sangmin Lee, MD, Michael B. Samuel, MD, Justin D. Kaner, MD, Ellen Ritchie, MD, Monica L. Guzman, PhD, Gail J. Roboz, MD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-140694

Published: 2020

Journal Articles

Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia in the Expansion Cohort of a Phase 1b Study

Naval Daver, MD, Jessica K. Altman, MD, Joseph Maly, MD, Mark Levis, MD PhD, Ellen Ritchie, MD, Mark Litzow, MD, James K. McCloskey, MD, Catherine C. Smith, MD, Gary J. Schiller, MD, Terrence Bradley, MD, Ramon V. Tiu, MD, Wan-Jen Hong, MD, Bo Tong, PhD, Qin Qin, MS, Kimberley Dilley, MD MPH, Alexander E. Perl, MD

Blood (2020) 136 (Supplement 1): 20–22.

https://doi.org/10.1182/blood-2020-139705

Published: 2020

Journal Articles

Interferon in Polycythemia Vera (PV) Yields Improved Myelofibrosis-Free and Overall Survival

Ghaith Abu-Zeinah, MD, Spencer Krichevsky, BS, Tatiana Cruz, MD, Gabriela Hoberman, BA, Niamh Savage, BA, Ellen Ritchie, MD, Joseph Scandura, MDPhD, Richard T. Silver, MD

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-141796

Published: 2020

Journal Articles

Ruxolitinib can cause weight gain by blocking leptin signaling in the brain via JAK2/STAT3

Nicole Mollé, Spencer Krichevsky, Pouneh Kermani, Richard T. Silver, Ellen Ritchie, Joseph M. Scandura

Blood (2020) 135 (13): 1062–1066.

https://doi.org/10.1182/blood.2019003050

Published: 2020

Includes: Supplemental data

Journal Articles

Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea

Blood (2019) 134 (18): 1498–1509.

https://doi.org/10.1182/blood.2019000428

Published: 2019

Includes: Supplemental data

Journal Articles

A Phase 1/2 Study of NS-018, an Oral JAK2 Inhibitor, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (pPV MF), or Post-Essential Thrombocythemia Myelofibrosis (pET MF)

Srdan Verstovsek, MD, Moshe Talpaz, MD, Ellen Ritchie, MD, Martha Wadleigh, MD, Olatoyosi Odenike, MD, Catriona Jamieson, MD PhD, Brady Stein, MD, Tomonori Uno, PhD, Ruben A. Mesa

Blood (2015) 126 (23): 2800.

https://doi.org/10.1182/blood.V126.23.2800.2800

Published: 2015

Journal Articles

Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin Plus Cytarabine Versus Placebo Plus Cytarabine: Results of a Phase 3 Double-Blind Randomized Controlled Multinational Study (VALOR)

Blood (2014) 124 (21): LBA-6.

https://doi.org/10.1182/blood.V124.21.LBA-6.LBA-6

Published: 2014

NARROW

Pre-Transplant Multiparameter Flow Cytometric Measurable Residual Disease in Acute Myeloid Leukemia As an Independent Prognostic Factor for Survival after Myeloablative Allogeneic Hematopoietic Cell Transplantation

Prospective Assessment of Measurable Residual Disease Kinetics in Intensively Treated Patients with Acute Myeloid Leukemia - Results of the Polish Adult Leukemia Group PALG-AML1/2016 Study

A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)

Association of Inflammatory Cytokines with Clonal Hematopoiesis and Progression to Acute Myeloid Leukemia

PTPN11 mutations Confer Adverse Outcomes and Therapy Resistance in Older Patients with Acute Myeloid Leukemia (AML)

Safety and Efficacy of Lower Intensity Induction Therapy with Intravenous Prexigebersen (BP1001) in Patients with High-Risk and Relapsed/Refractory Acute Myeloid Leukemia (AML)

Impact of Peri-Transplant Molecular Mutations on Outcomes of AML Patients Undergoing Fludarabine/Melphalan Conditioned Allogeneic Stem Cell Transplant

Comparing Outcomes between Liposomal Daunorubicin/Cytarabine (CPX-351) and HMA+Venetoclax As Frontline Therapy in Acute Myeloid Leukemia

Venetoclax in Combination with Gilteritinib Demonstrates Molecular Clearance of FLT3 mutation in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia

The Prognostic Value of Early Measurable Residual Disease Assessment in Patients with Acute Myeloid Leukemia Treated with Intensive Chemotherapy - Preliminary Results of Polish Adult Leukemia Group PALG-AML1/2016 Study

Hematopoietic Stem and Progenitor Cell Fitness As a Novel Prognostic and Monitoring Biomarker for JAK2 V617F Myeloproliferative Neoplasms (MPNs)

Community Versus Academic Practice in Essential Thrombocythemia and Myelofibrosis: Differences in Clinical Characteristics, Diagnosis, Treatment Patterns, and Symptom Burden (Analysis of Data from the MOST Study)

Pain and Opioid Use in Patients with FLT3 Mutation-Positive Relapsed/Refractory AML: A Subanalysis of Patient-Reported Outcomes from the Admiral Trial

A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)

Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia in the Expansion Cohort of a Phase 1b Study

Interferon in Polycythemia Vera (PV) Yields Improved Myelofibrosis-Free and Overall Survival

Ruxolitinib can cause weight gain by blocking leptin signaling in the brain via JAK2/STAT3

Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea

A Phase 1/2 Study of NS-018, an Oral JAK2 Inhibitor, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (pPV MF), or Post-Essential Thrombocythemia Myelofibrosis (pET MF)

Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin Plus Cytarabine Versus Placebo Plus Cytarabine: Results of a Phase 3 Double-Blind Randomized Controlled Multinational Study (VALOR)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only